$8.84 Million in Sales Expected for Atara Biotherapeutics, Inc. (NASDAQ:ATRA) This Quarter

Posted by on Jun 10th, 2022

Wall Street analysts predict that Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Rating) will post sales of $8.84 million for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Atara Biotherapeutics’ earnings, with the lowest sales estimate coming in at $5.80 million and the highest estimate coming in at $14.73 million. Atara Biotherapeutics posted sales of $3.87 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 128.4%. The firm is scheduled to issue its next earnings results on Monday, January 1st.

On average, analysts expect that Atara Biotherapeutics will report full year sales of $53.28 million for the current year, with estimates ranging from $25.31 million to $75.30 million. For the next year, analysts forecast that the company will report sales of $82.67 million, with estimates ranging from $29.34 million to $136.00 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Atara Biotherapeutics.

Atara Biotherapeutics (NASDAQ:ATRA – Get Rating) last posted its quarterly earnings results on Thursday, May 5th. The biotechnology company reported ($0.87) earnings per share for the quarter, topping the consensus estimate of ($0.98) by $0.11. Atara Biotherapeutics had a negative return on equity of 122.18% and a negative net margin of 1,451.79%. During the same period in the previous year, the company earned ($0.86) earnings per share.

Several equities research analysts have recently weighed in on the company. Citigroup downgraded Atara Biotherapeutics from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $15.00 to $8.00 in a report on Monday, May 9th. Canaccord Genuity Group lowered their price objective on Atara Biotherapeutics from $78.00 to $67.00 in a research report on Tuesday, March 1st. HC Wainwright reduced their target price on Atara Biotherapeutics from $31.00 to $29.00 and set a “buy” rating for the company in a research note on Monday, May 23rd. JPMorgan Chase & Co. dropped their target price on Atara Biotherapeutics from $27.00 to $22.00 and set an “overweight” rating on the stock in a research report on Monday, March 28th. Finally, StockNews.com cut Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, May 17th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $26.88.

In related news, CFO Utpal Koppikar sold 5,582 shares of Atara Biotherapeutics stock in a transaction that occurred on Tuesday, May 17th. The stock was sold at an average price of $5.32, for a total transaction of $29,696.24. Following the completion of the transaction, the chief financial officer now directly owns 207,592 shares in the company, valued at approximately $1,104,389.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Pascal Touchon sold 13,913 shares of Atara Biotherapeutics stock in a transaction that occurred on Tuesday, May 17th. The stock was sold at an average price of $5.32, for a total transaction of $74,017.16. Following the completion of the sale, the chief executive officer now directly owns 486,313 shares of the company’s stock, valued at $2,587,185.16. The disclosure for this sale can be found here. In the last three months, insiders have sold 26,591 shares of company stock worth $141,464. Corporate insiders own 4.00% of the company’s stock.

A number of hedge funds have recently modified their holdings of the business. JPMorgan Chase & Co. raised its stake in shares of Atara Biotherapeutics by 10.4% in the 1st quarter. JPMorgan Chase & Co. now owns 8,189,899 shares of the biotechnology company’s stock valued at $76,085,000 after purchasing an additional 772,777 shares in the last quarter. Maverick Capital Ltd. grew its position in Atara Biotherapeutics by 2.0% in the 3rd quarter. Maverick Capital Ltd. now owns 7,855,824 shares of the biotechnology company’s stock worth $140,619,000 after purchasing an additional 151,148 shares during the last quarter. BlackRock Inc. grew its position in Atara Biotherapeutics by 2.2% in the 4th quarter. BlackRock Inc. now owns 7,816,552 shares of the biotechnology company’s stock worth $123,190,000 after purchasing an additional 164,961 shares during the last quarter. State Street Corp boosted its holdings in shares of Atara Biotherapeutics by 45.1% in the first quarter. State Street Corp now owns 6,273,617 shares of the biotechnology company’s stock valued at $58,282,000 after acquiring an additional 1,949,418 shares in the last quarter. Finally, Point72 Asset Management L.P. boosted its holdings in shares of Atara Biotherapeutics by 99.0% in the fourth quarter. Point72 Asset Management L.P. now owns 4,613,700 shares of the biotechnology company’s stock valued at $72,712,000 after acquiring an additional 2,295,400 shares in the last quarter.

NASDAQ:ATRA opened at $5.67 on Friday. The company has a market capitalization of $529.61 million, a P/E ratio of -1.56 and a beta of 1.94. Atara Biotherapeutics has a 12 month low of $4.61 and a 12 month high of $20.04. The business’s 50-day moving average is $6.58 and its 200 day moving average is $11.48.

Atara Biotherapeutics Company Profile (Get Rating)

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma.

Featured Articles

Get a free copy of the Zacks research report on Atara Biotherapeutics (ATRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Atara Biotherapeutics (NASDAQ:ATRA)

Want More Great Investing Ideas?

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.